Our store location is now open with huge sales on RUO products. Monday, Wednesday and Friday 11 a.m. to 6 p.m., Saturday 11 a.m. to 4 p.m.
Marvel Peptide USA
Reta-3

Reta-3

Supplied as a lyophilized powder in a sealed vial, for laboratory research use only.

from $35.00 per vial

Strengths and prices

StrengthPrice per vial AvailabilityBatch
10 mg $35.00 In stock HY0722-36
15 mg $45.00 In stock NOLOT
20 mg $55.00 In stock HY0722-34
30 mg $70.00 In stock RT-2607-0044
40 mg $85.00 Out of stock —
50 mg $95.00 In stock RT-2607-0046
60 mg $105.00 In stock —

Every vial carries its batch code and a QR that opens the certificate of analysis for that exact batch. No account is needed to read one.

What it is

Reta-3 is a synthetic peptide of the incretin class that acts at three receptors: GIP, GLP-1 and glucagon.

Identity

TypeSynthetic acylated peptide, triple receptor agonist
ReceptorsGIP, GLP-1 and glucagon

Reta-3 is a synthetic acylated peptide of the incretin class with agonist activity at the GIP, GLP-1 and glucagon receptors. Compounds of this class are single-chain peptides of about 39 amino acids built on the sequence of GIP, with non-natural residues such as aminoisobutyric acid substituted at positions that peptidases would otherwise cleave, and a C20 fatty diacid attached through a short linker to a lysine side chain so that the peptide binds albumin and circulates for days. The compound's generic name, formula and CAS number are left off this page by design. It is supplied as a white lyophilized powder in a sealed vial.

What the published research covers

Compounds of this class have been studied in phase 2 and phase 3 clinical trials, with results published in peer-reviewed journals.

Reta-3 belongs to the newest branch of the incretin class. Peptides acting at the GLP-1 receptor alone entered the clinic in 2005; dual GIP and GLP-1 receptor agonists followed in the 2010s; triple agonists add activity at the glucagon receptor to act on energy expenditure as well as intake. The most studied compound of the class was disclosed in 2022: in receptor assays it showed balanced glucagon and GLP-1 receptor activity with greater GIP receptor activity, and in obese mice it lowered body weight through both higher energy expenditure and lower intake (Coskun, 2022).

The human data are sponsor-run trials. A 48-week phase 2 trial in 338 adults with obesity reported body-weight changes of -8.7 to -24.2 percent across the treatment groups against -2.1 percent on placebo (Jastreboff, 2023); a parallel phase 2 trial covered adults with type 2 diabetes (Rosenstock, 2023). A 48-week phase 2a trial in 98 participants with steatotic liver disease reported liver-fat changes at 24 weeks of up to -82.4 percent in the highest group against +0.3 percent on placebo (Sanyal, 2024). Phase 3 results appeared in 2026: an 80-week trial in 2,339 adults with obesity reported -17.6, -23.7 and -25.0 percent in its three treatment groups against -3.9 percent on placebo (Jastreboff, 2026), and a trial in 1,152 adults with obesity and type 2 diabetes reported -18.8 percent in the highest group against -5.1 percent (Bellido, 2026). Gastrointestinal adverse events were the most common in every trial.

No compound of this class is approved by any regulator. Outcomes beyond 80 weeks, cardiovascular endpoints and what happens after stopping are unreported. Every published study concerns the sponsor's investigational compound, not any research-grade material.

Regulatory status

Not approved by the FDA for any use. Supplied for laboratory research only.

Testing and documentation

Identity is confirmed by mass spectrometry and purity by HPLC. The certificate of analysis for the batch is reachable from the code on the vial.

Questions laboratories ask

What strengths is Reta-3 offered in?
Vials of 5, 10, 15, 20, 30, 40 and 50 mg, as listed on the product page. The amount is on the vial label and on the certificate of analysis for the batch.
Is Reta-3 an approved drug?
No. No compound of this class is approved by the FDA for any use. Reta-3 is a research peptide supplied for laboratory research only, under the Research Use Agreement.
Is there a certificate of analysis for each batch?
Yes. Every batch is tested by an independent laboratory: identity by mass spectrometry and purity by HPLC. The QR code on the vial opens the certificate for that exact batch, and it is also reachable from the product page and your account.
How does it ship?
From Montana, the next business day for an order paid by card, by FedEx or USPS. We ship to addresses in the United States only and not to freight forwarders.

References

  1. Coskun T et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism. PubMed 35985340
  2. Jastreboff AM et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. New England Journal of Medicine. PubMed 37366315
  3. Rosenstock J et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. PubMed 37385280
  4. Sanyal AJ et al. (2024). Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. PubMed 38858523
  5. Jastreboff AM et al. (2026). Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. New England Journal of Medicine. PubMed 42814954
  6. Bellido V et al. (2026). Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. PubMed 42810372

How it ships

Next day
Dispatched from Montana on all orders, packed and tracked.
One vial
The minimum order. You pay by card at checkout, or by invoice before the order ships.
Your batch
The certificate of analysis for the batch you receive is on the vial and on this site.

Ordering

Ordering needs an account. A retail account opens as soon as you request it and costs nothing. You pay by card at checkout, or by invoice before the order ships. A wholesale account is reviewed before it opens.

Research use only

This product is a research chemical sold solely for in-vitro laboratory research by qualified persons. It is not a drug, food, supplement or cosmetic, has not been evaluated by the FDA, and must not be administered to any person or animal. Read the full agreement

More from the catalog

All peptides, strengths and prices →